Chang, Yung-Nien
https://orcid.org/0000-0003-2780-7800
Mayo Clinic
PapiVax Biotech, Inc., Taipei, Taipei, Taiwan
Citations 1
677 Phase II trial assessing safety, efficacy and immune correlates of heterologous prime-boost with pBI-11 (IM) and TA-HPV (IM) plus pembrolizumab for advanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal cancer
Heimann-Nichols, Ellen, Chang, Yung-Nien , Gibson, Michael K. , Savvides, P. , Worden, Francis P. , Wu, T.‐C. , Roden, Richard
Regular and Young Investigator Award Abstracts | October 31, 2023 | Volume: No volume available | Issue: No issue available | Pages: A768-A768
